Clene Inc.'s Participation in Upcoming Investor Conferences: Key FAQs
Summary
Clene Inc., a clinical-stage biopharmaceutical company, announced its participation in two investor conferences to discuss its focus on treating neurodegenerative diseases through mitochondrial health improvement.
What is Clene Inc. and what does it focus on?
Clene Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as ALS, Parkinson’s disease, and multiple sclerosis.
Which investor conferences will Clene Inc. participate in?
Clene Inc. will participate in the 2024 Maxim Healthcare Virtual Summit on October 15, 2024, and the ThinkEquity Conference 2024 on October 30, 2024, in New York.
What time is Clene Inc.’s presentation at the Maxim Healthcare Virtual Summit?
Clene Inc.’s presentation at the 2024 Maxim Healthcare Virtual Summit is scheduled for 2:30 p.m. ET on October 15, 2024.
Where can I find more information about Clene Inc.’s press release?
The full press release can be viewed at https://ibn.fm/CDyv8.
What is CNM-Au8(R) and what does it do?
CNM-Au8(R) is an investigational first-in-class therapy by Clene Nanomedicine Inc. that improves central nervous system cells’ survival and function by targeting mitochondrial function and the NAD pathway while reducing oxidative stress.
Where is Clene Inc. based?
Clene Inc. is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland.
How can I contact Clene Inc. for more information?
For more information, you can visit www.Clene.com or contact IBN at Editor@InvestorBrandNetwork.com.
What are the implications of Clene Inc.’s research?
Clene Inc.’s research has the potential to offer new treatments for neurodegenerative diseases by focusing on mitochondrial health and neuronal function, addressing a significant unmet medical need.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 127954